In the latest episode of our podcast, we had the pleasure of speaking with Max Ostermeier. He is the Co-Founder and CEO of ImplantData Ophthalmic Products and has an impressive background, transitioning from a career in finance to becoming a serial entrepreneur in the medtech industry. His innovative spirit and dedication to improving patient care have led to the development of several groundbreaking technologies. Through his ventures, he has a successful track record of regulatory approval, fundraising, and strategic exits through acquisition.
Today, Max’s work through ImplantData Opthalmic Products is focused on developing an implantable sensor for continuous monitoring of intraocular pressure in glaucoma patients. Implandata Ophthalmic Products GmbH is a digital health company, based in Hannover Germany. The company’s mission is to address a vastly underserved need in care of glaucoma patients, by combining innovative medical technology with state of the art information technology.
Below is a summary of our conversation.
From Finance to Medtech Innovator
Max’s career began in Finance, but he quickly realized his true passion lay elsewhere. With the guidance of a mentor, he transitioned into the biotech sector, eventually becoming the CEO of a newly formed biotech company. This role ignited his enthusiasm for creating impactful technologies. After several successful ventures, including developing a portable device for detecting traumatic brain injuries and a microsensor for measuring brain pressure in hydrocephalus patients, Max founded Implandata Ophthalmic Products, IOP, to address a significant unmet need in ophthalmology.
Revolutionizing Glaucoma Care
ImplantData Ophthalmic Products is dedicated to improving the management of glaucoma, a chronic eye disease and the leading cause of permanent vision loss worldwide. Traditional methods of monitoring intraocular pressure are limited to infrequent office visits, providing only a snapshot of the patient’s condition. Recognizing the dynamic nature of Implandata, Max and his team developed a tiny implantable sensor that continuously monitors eye pressure, providing real-time data to both patients and their doctors.
Leveraging Technology for Better Outcomes
The implantable sensor, inspired by tire pressure monitoring systems in the automotive industry, allows for continuous, remote monitoring of intraocular pressure. This breakthrough technology empowers patients to self-monitor their condition and enables doctors to provide more personalized and timely care. The sensor’s data is transmitted via the patient’s smartphone to a cloud-based database, where it can be accessed by the patient’s eye doctor through a secure dashboard. This innovation not only improves patient outcomes but also helps manage the growing number of glaucoma patients more efficiently.
Overcoming Challenges and Embracing Opportunities
Max discussed the challenges of developing durable, long-term sensors suitable for chronic disease management. He emphasized the importance of having a strong, experienced team and the value of involving key opinion leaders early in the development process. Max also highlighted the favorable environment for innovation in eye care, driven by advancements in technology and the increasing tech-savviness of patients.
Future Directions and Vision
Looking ahead, Max and his team at IOP are focused on expanding their product’s reach in Europe and entering the U.S. market, leveraging their breakthrough device designation from the FDA. They are also exploring applications for their technology in other chronic diseases, such as liver and cardiovascular conditions. Max and his team believes in the power of a single idea to change the world and remains dedicated to providing better care for patients through innovative solutions.
To stay connected with USD Discovery District, please follow us on LinkedIn.
We are leasing now! Please visit usddiscovery.com/lease for more information.
Implandata: www.implandata.com
